NewAmsterdam Pharma Reports the Completion of Patient Enrollment in P-III trial (BROOKYLN) of Obicetrapib for Heterozygous Familial Hypercholesterolemia
- The patient enrolment has been completed in the P-III trial evaluating obicetrapib in 354 adult patients with HeFH whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-lowering therapy across 10 countries in North America, the EU & Africa. The results are expected in H2’24
- The trial's primary objective is to assess obicetrapib's impact on LDL-C levels & secondary objectives incl. assessing the effect on non-HDL-C, ApoB & lipoprotein (a). The safety & tolerability profile of obicetrapib is also being assessed during the trial
- Obicetrapib is also being studied in the 2 P-III trials (BROADWAY) & (BROOKLYN) as an adjunct to maximally tolerated lipid-lowering therapies to enhance LDL-lowering for high-risk CVD patients
Ref: Globenewswire | Image: NewAmsterdam Pharma
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.